Cerity Partners’s Praxis Precision Medicines PRAX Stock Holding History

Cerity Partners’s Portfolio PRAX Stock Details PRAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$515K	Sell	1,599 -2,328	-59%	-$720K	﹤0.01%	2268
2025 Q4	$1.16M	Sell	3,927 -1,523	-28%	-$284K	﹤0.01%	1640
2025 Q3	$289K	Sell	5,450 -161	-3%	-$7.81K	﹤0.01%	2302
2025 Q2	$236K	Buy	+5,611	New	+$214K	﹤0.01%	2269
2025 Q1	–	Sell	-4,364	Closed	-$334K	–	2593
2024 Q4	$334K	Sell	4,364 -24	-0.5%	-$1.74K	﹤0.01%	1982
2024 Q3	$252K	Buy	+4,388	New	+$237K	﹤0.01%	2183
2024 Q2	–	Sell	-4,261	Closed	-$260K	–	2371
2024 Q1	$260K	Buy	+4,261	New	+$191K	﹤0.01%	1950

Other funds holding PRAX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Cerity Partners's PRAX Position: Q1 2026 in Review

Cerity Partners reduced its Praxis Precision Medicines (PRAX) stake by 59% in Q1 2026, selling an estimated $720K and leaving 1,599 shares worth $515K. The position accounts for ﹤0.01% of the portfolio, ranked #2268.

Cerity Partners first reported a position in PRAX in Q1 2024 and has held it in 7 quarters since. The position peaked at $1.16M in Q4 2025. 289 funds tracked by Wall St. Rank hold PRAX as of Q1 2026.

Cerity Partners held 1,599 shares of Praxis Precision Medicines worth $515K as of Q1 2026.
Cerity Partners sold 2,328 Praxis Precision Medicines shares in Q1 2026, an estimated $720K.
Praxis Precision Medicines made up ﹤0.01% of Cerity Partners's portfolio in Q1 2026, its #2268 holding.
Cerity Partners first reported a position in Praxis Precision Medicines in Q1 2024 and has held it in 7 quarters since.
Cerity Partners's Praxis Precision Medicines position peaked at $1.16M in Q4 2025.
289 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q1 2026.

Based on Cerity Partners's 13F filing for Q1 2026, filed 15 May 2026.